During the last session, CureVac N.V (NASDAQ:CVAC)’s traded shares were 0.47 million, with the beta value of the company hitting 2.58. At the end of the trading day, the stock’s price was $2.66, reflecting an intraday gain of 3.91% or $0.1. The 52-week high for the CVAC share is $6.30, that puts it down -136.84 from that peak though still a striking 16.92% gain since the share price plummeted to a 52-week low of $2.21. The company’s market capitalization is $596.65M, and the average intraday trading volume over the past 10 days was 0.68 million shares, and the average trade volume was 470.77K shares over the past three months.
CureVac N.V (CVAC) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.29. CVAC has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.12.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CureVac N.V (NASDAQ:CVAC) trade information
CureVac N.V (CVAC) registered a 3.91% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.91% in intraday trading to $2.66, hitting a weekly high. The stock’s 5-day price performance is 4.72%, and it has moved by -2.21% in 30 days. Based on these gigs, the overall price performance for the year is -51.19%. The short interest in CureVac N.V (NASDAQ:CVAC) is 4.56 million shares and it means that shorts have 12.68 day(s) to cover.
The consensus price target of analysts on Wall Street is $29, which implies an increase of 90.83% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $21 and $37 respectively. As a result, CVAC is trading at a discount of -1290.98% off the target high and -689.47% off the low.
CureVac N.V (CVAC) estimates and forecasts
Statistics show that CureVac N.V has outperformed its competitors in share price, compared to the industry in which it operates. CureVac N.V (CVAC) shares have gone down -27.91% during the last six months, with a year-to-date growth rate more than the industry average at 147.66% against 17.90. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 69.23% this quarter and then jump 47.99% in the quarter after that. In the rating firms’ projections, revenue will increase 885.84% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 7.8M as predicted by 5 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 13.56M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 22.6M and 12.37M respectively. In this case, analysts expect current quarter sales to shrink by -65.49% and then jump by 9.57% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -23.15%. While earnings are projected to return 168.02% in 2024, the next five years will return -10.76% per annum.
CVAC Dividends
CureVac N.V is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 2.42 million shares, is of POINT72 ASSET MANAGEMENT, L.P.’s that is approximately 1.0802% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $8.24 million.
Also, the Mutual Funds coming in first place with the largest holdings of CureVac N.V (CVAC) shares are iShares Biotechnology ETF and iShares Core MSCI EAFE ETF . Data provided on Sep 30, 2024 indicates that iShares Biotechnology ETF owns about 675.44 shares. This amounts to just over 0.30 percent of the company’s overall shares, with a $1.8 million market value. The same data shows that the other fund manager holds slightly less at 575.4, or about 0.26% of the stock, which is worth about $1.53 million.
